Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Paul A. Meyers(Memorial Sloan Kettering Cancer Center), Joseph A. Ludwig(The University of Texas MD Anderson Cancer Center), Matteo Trucco(Cleveland Clinic), AeRang Kim(Children's National), Angela Pietrofeso(Therapeutics Clinical Research), Peter M. Anderson(Mayo Clinic in Arizona), Margaret E. Macy(Children's Hospital Colorado), Richard F. Riedel(Heidelberg University), James B. Breitmeyer(Therapeutics Clinical Research), Lara E. Davis(Oregon Health & Science University), Jeffrey A. Toretsky(Georgetown University), Noah Federman(University of California, Los Angeles), Najat C. Daw(The University of Texas MD Anderson Cancer Center), Ravin Ratan(The University of Texas MD Anderson Cancer Center)
Cited by 36
Related Papers
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711